Form D · Pharmaceuticals
Oyster Point Pharma, Inc.
Princeton, NJ · CIK 0001720725
Offering snapshot reported Feb 27, 2019 · SEC filing
- Reported sold
- $85M Offering amount: $93M
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 15, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 27, 2019 | Initial | $84,999,985 | No comparison | 7 | SEC filing |
| Oct 25, 2017 | Initial | $28,614,800 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-333703
Source: Form D, filed Feb 27, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| D. Michael Ackermann | Director |
| Ali Behbahani | Director |
| William J Link | Director |
| Mark A. Murray | Director, Executive |
| Jeffrey Nau | Director, Executive |
| Clare Ozawa | Director |
| Benjamin Tsai | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
700 Alexander Park Drive Suite 301
Princeton, NJ, 08540
Princeton, NJ, 08540